
Novel fluorescent Bortezomib-GV1001 conjugate for monitoring the delivery of the proteasome ингибитор bortezomib (Btz) to HT-29 cancer cells, exhibiting an improved cytoplasmic availability
Novel fluorescent Bortezomib-GV1001 conjugate for monitoring the delivery of the proteasome inhibitor bortezomib (Btz) to HT-29 cancer cells, exhibiting an improved cytoplasmic availability
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.